Are you unsure whether Cipla Actin is actually the best option for your weight-gain requirements? It’s a worthwhile question to investigate. Losing weight can be difficult for some people, but ...

Cipla is facing moderate headwinds at the moment. India business underwent a soft two quarters, US business faced supply issues in one main product and Trump tariff pressure has impacted the ...

"Formosa Pharma welcomes this partnership with Cipla, a well-renowned and respected global pharmaceutical brand. We appreciate their recognition and desire to add APP13007 to their rich portfolio of ...

Stock market today: The domestic benchmark indices, Nifty 50 and Sensex, retraced their earlier gains on Monday, as worries over global trade kept investors cautious, while Reliance Industries, a ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

New Delhi: Cancer patients facing prohibitive treatment costs in India can hope for relief: the nation's top drugmakers have started manufacturing key medicines for such diseases in the country.

Cipla's shares are currently priced at Rs 1510.10, reflecting a modest increase of 0.74% today, suggesting investor confidence. Cipla's shares are currently priced at Rs 1507.55, reflecting a daily ...

Cipla's current price stands at Rs 1429.0, reflecting a 1.95% rise today, while its three-month returns have dipped by 4.53%. Cipla has achieved a positive price breakout and is trading above its ...

Formosa and Cipla's agreement grants Cipla exclusive marketing rights for APP13007 in 11 countries, enhancing Cipla's ophthalmology portfolio. APP13007, approved by the FDA in March 2024, provides a ...